Skip to Content

Investor Relations

Investor Relations

Company Overview

Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. Monoclonal antibodies, or mAbs, are a well-established therapeutic class across many disease areas; however, they have yet to be broadly utilized for the prevention or treatment of acute bacterial and viral infections, where they hold the potential to address serious unmet medical needs. Unlike antibiotics that propagate resistance, disrupt both disease-causing and beneficial bacteria and have adverse off-target effects, mAbs have the ability to precisely bind only to an intended target, thereby avoiding these undesired consequences. Our expertise lies in applying our deep understanding of infectious disease pathogenesis paired with our ability to access some of the most advanced mAb discovery techniques and platforms available today. We have used this expertise to discover and develop novel mAbs with multiple mechanisms of action and high potency against their intended targets.
 

News Releases

August 13, 2018 at 8:00 AM EDT

WALTHAM, Mass. and VIENNA, Austria , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, today reported financial results for the second

June 28, 2018 at 7:00 AM EDT

Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment  and Evaluate Complete Clinical Trial Dataset Arsanis to Continue Focus on Development of ASN500 for Prevention of RSV Infection WALTHAM, Mass. and VIENNA, Austria , June 28, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc.

June 14, 2018 at 8:00 AM EDT

Second recent transaction with Bravos Biosciences consolidates development of Arsanis gram-negative mAb candidates with global experts in anti-infective drug development WALTHAM, Mass. and VIENNA, Austria , June 14, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc.

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Top